Výsledky vyhledávání - "Price, Mylissa K."

Lowering Out of Pocket Drug Costs for Consumers

Autor: Price, Mylissa K.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6b3b035955513e665c73f75c2254711

A Comparison of the Costs Associated with the Administration of Select High-cost Infused Medications in Three Sites of Care for a State Medicaid Population

Autor: Bagwell, Sage, Lavitas, Pavel, Pomfret, Thomas C., Greenwood, Bonnie C., Trask, Nicole M., Tran, Stephanie, Schiff, Nancy L., Hydery, Tasmina, Leto, Patricia, Price, Mylissa K., Alper, Caroline J., Lenz, Kimberly J., Jeffrey, Paul L.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9e81920c98dca9ede43060b973c9d3b

Zobrazit plný text záznamu

Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population

Autor: Kouris, George, Hydery, Tasmina, Greenwood, Bonnie C., Lavitas, Pavel, Alper, Caroline J., Price, Mylissa K., Clements, Karen M., Lenz, Kimberly J., Jeffrey, Paul L.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3008888850d4c5db4aca10c431984e6c

Zobrazit plný text záznamu

Evaluation of Progesterone Agent Utilization and Birth Outcomes in a State Medicaid Plan

Autor: Hydery, Tasmina, Price, Mylissa K., Greenwood, Bonnie C., Takeshita, Mito, Mauro, Rose, Kunte, Parag, Lenz, Kimberly J., Jeffrey, Paul L.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b410f57627b451d960c5b1ad663fb599

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of Ivacaftor on Medication Use, Hospital and Outpatient Provider Visits and Associated Costs in a Medicaid Population

Autor: Leo, Sam M., Lowe, Maria M., Alper, Caroline J., Lee, Karen W., Lenz, Kimberly J., Liou, Gloria, Pomfret, Thomas C., Price, Mylissa K., Tesell, Mark A., Jeffrey, Paul L.

BACKGROUND: Ivacaftor is the first Food and Drug Administration-approved medication to treat an underlying genetic defect in patients with cystic fibrosis (CF). With an approximate annual cost of $300,000 per patient, ivacaftor may have a profound fi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff575ba797c1ce101713b4947a53e149

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání